(NASDAQ: BNTX) Biontech Se's forecast annual revenue growth rate of 0.73% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.39%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.64%.
Biontech Se's revenue in 2024 is $2,935,053,763.On average, 7 Wall Street analysts forecast BNTX's revenue for 2024 to be $707,632,014,505, with the lowest BNTX revenue forecast at $564,161,205,273, and the highest BNTX revenue forecast at $789,710,628,126. On average, 7 Wall Street analysts forecast BNTX's revenue for 2025 to be $713,309,855,960, with the lowest BNTX revenue forecast at $425,374,543,922, and the highest BNTX revenue forecast at $946,585,840,652.
In 2026, BNTX is forecast to generate $711,833,579,146 in revenue, with the lowest revenue forecast at $467,599,388,973 and the highest revenue forecast at $1,087,164,954,045.